Vietnam Atopic Dermatitis Therapeutics Market Report 2022 to 2030

Vietnam Atopic Dermatitis Therapeutics Market Analysis

$ 3999

The Vietnam Atopic Dermatitis Therapeutics Market was valued at US $62 Mn in 2022, and is predicted to grow at (CAGR) of 9.03% from 2023 to 2030, to US $123 Mn by 2030. The key drivers of this industry include the increased burden of Atopic Dermatitis (AD), improving healthcare infrastructure, shifting patient preferences, and others. The industry is primarily dominated by players such as Sanofi, Pharmacity, Merck, AbbVie, Domesco, Novartis, and Johnson & Johnson, among others.

ID: IN10VNPH435 CATEGORY: Pharmaceuticals GEOGRAPHY: Vietnam AUTHOR: Riddhi Solanki

Buy Now

Vietnam Atopic Dermatitis Therapeutics Market Analysis: Executive Summary

The Vietnam Atopic Dermatitis Therapeutics Market is at around US $62 Mn in 2022 and is projected to reach US $123 Mn in 2030, exhibiting a CAGR of 9.03% during the forecast period.

Atopic dermatitis (AD), commonly known as eczema, is a chronic, inflammatory skin condition characterized by redness, itching, and inflammation. It often manifests in localized patches across different areas of the body and can be aggravated by factors such as dry skin, stress, and exposure to specific irritants or allergens. Prominent symptoms include intense itching, redness, dryness, and the formation of small, fluid-filled blisters that may release fluid and form crusts. Treatment typically involves a comprehensive approach, including the use of emollients for skin moisturization, topical corticosteroids to alleviate inflammation, and, in severe cases, systemic immunosuppressants. Various pharmaceutical companies produce medications for atopic dermatitis, with notable examples being Regeneron Pharmaceuticals and Sanofi's Dupixent (Dupilumab), Pfizer's Eucrisa (Crisaborole), and Novartis's Elidel (Pimecrolimus).

The estimated overall prevalence of atopic dermatitis (AD) in Vietnam is in the range of 5% to 10%. The market is being driven by crucial factors such as the surge in the prevalence of AD, improving healthcare infrastructure, and shifting patient preferences in therapeutics industry. However, conditions such as limited affordability, the dominance of generic medications, and a lack of human resources limit the growth and potential of the market.

Market Dynamics

Market Growth Drivers

Surge in prevalence of AD: The overall prevalence of AD is estimated to be approximately in the range of 5%–10% in Vietnam. The escalating prevalence of atopic dermatitis, particularly among children, generates an increasing need for efficacious treatment alternatives. Increased exposure to environmental triggers such as pollution and allergens contributes to a surge in cases of atopic dermatitis (AD).

Improving healthcare infrastructure: Vietnam's strong economic growth results in increased disposable incomes, enabling a larger portion of the population to afford treatments for AD. The government's initiatives to broaden health insurance coverage enhance access to healthcare services and medications for AD.

Shifting patient preferences: Patients are increasingly exploring alternatives that are non-steroidal and free of corticosteroids, driven by concerns about potential side effects. Rising awareness of biologics: A growing understanding of the efficacy of biologic medications for moderate-to-severe atopic dermatitis is fueling demand.

Market Restraints

Limited affordability: Prolonged management involving medications, moisturizers, and emollients imposes a notable financial strain on patients. The health insurance system in Vietnam provides partial coverage for AD treatments, yet it comes with restrictions and exclusions, leaving a considerable number of patients accountable for out-of-pocket expenses and hindering market penetration.

Dominance of generics: The market is saturated with generic topical steroids and emollients, triggering price wars and compressing profit margins for pharmaceutical companies. This discourages investments in the research and development of innovative therapies.

Limited human resources: Vietnam encounters a shortage of adequately trained dermatologists and healthcare professionals with expertise in managing atopic dermatitis, potentially limiting the quality of care and adherence to treatment plans.

Healthcare Policies and Regulatory Landscape

Vietnam's healthcare regulatory landscape is governed by the Ministry of Health (MOH), with the Drug Administration of Vietnam (DAV) being the primary regulatory authority overseeing pharmaceuticals. The DAV is responsible for the registration, evaluation, and approval of drugs and pharmaceutical products in Vietnam. Companies seeking to introduce new drugs to the Vietnamese market must go through the DAV's regulatory processes, which involve comprehensive assessments of product safety, quality, and efficacy. The registration and licensing of pharmaceutical products require adherence to Vietnamese regulations and standards to ensure the protection of public health.

For new entrants in the Vietnamese healthcare market, navigating the regulatory environment involves understanding and complying with the requirements set by the DAV and other relevant authorities. Obtaining licenses for pharmaceutical products requires the submission of detailed documentation, and companies need to work closely with regulatory agencies to meet the necessary standards. Vietnam has been evolving its regulatory framework to align with international standards and encourage foreign investment in its healthcare sector

Competitive Landscape

Key Players

Sanofi
GlaxoSmithKline
Novartis
AbbVie
Pierre Fabre
Bayer
Merck Sharp & Dohme
Johnson & Johnson
Domesco Pharmaceuticals
Pharmacity Holdings

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Vietnam Atopic Dermatitis Therapeutics Market Segmentation

By Drug Class

Corticosteroids
Calcineurin Inhibitors
Immunosuppressants
Biologic Therapy
PDE-4 Inhibitor
Antibiotics
Antihistamines
Emollients

By Route of Administration

Topic
Oral
Injectable

By Severity type

Mild
Moderate
Severe

By Age Group

18 years and below
19 years and above

By Distribution channel

Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Dermatology Clinics
Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.